Journal
MOLECULAR CANCER THERAPEUTICS
Volume 15, Issue 8, Pages 1879-1889Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1535-7163.MCT-15-0335
Keywords
-
Categories
Funding
- Cancer Prevention and Research Institute of Texas [RP110069, RP110441]
- NIH [RO1GM85575]
Ask authors/readers for more resources
Understanding the complex behavior of effector cells such as monocytes ormacrophages in regulating cancerous growth is of central importance for cancer immunotherapy. Earlier studies using CD20-specific antibodies have demonstrated that the Fc gamma receptor (Fc gamma R)-mediated transfer of the targeted receptors from tumor cells to these effector cells through trogocytosis can enable escape from antibody therapy, leading to the viewpoint that this process is protumorigenic. In the current study, we demonstrate that persistent trogocytic attack results in the killing of HER2-overexpressing breast cancer cells. Further, antibody engineering to increase FcgR interactions enhances this tumoricidal activity. These studies extend the complex repertoire of activities of macrophages to trogocytic-mediated cell death of HER2-overexpressing target cells and have implications for the development of effective antibody-based therapies. (C)2016 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available